NFKB1 and psoriasis: The current pharmacological treatments for psoriasis act through a variety of mechanisms, including, but not limited to, the inhibition of keratinocyte hyperproliferation, the restoration of normal cellular differentiation, the inhibition of multiple inflammatory signalling pathways (e.g., NF-κB, JAK-STAT3), and the attenuation of the inflammatory response (Li et al., 2023).